Exchange: NASDAQ·Updated 07:43 PM EDT
CADL logo

CADLCandel Therapeutics Inc

$10.22
$0.65
(6.79%)
Today
Closed $10.22
$0.04
(0.39%)
After Hours
EarningsAug 13
Mkt Cap$701.2M
Vol1.28M
News
all
press releases
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.
Stocktwits
More News
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.
Stocktwits
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...
Benzinga
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data
The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo.
Stocktwits
CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches
Candel Therapeutics is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene in patients with localized, intermediate- to high-risk prostate cancer
Stocktwits
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow
Candel Therapeutics generated investor buzz ahead of a key prostate cancer data readout, while its first-quarter loss came narrower than consensus estimates.
Stocktwits
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High - Here's What Happened
Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...
MarketBeat
Candel Therapeutics (CADL) to Release Earnings on Tuesday
Candel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-candel-therapeutics-inc-stock...
MarketBeat
Candel Therapeutics (NASDAQ:CADL) Stock Price Up 6.1% - Should You Buy?
Candel Therapeutics (NASDAQ:CADL) Trading 6.1% Higher - Here's Why...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.